Back to search

Article

Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotyping

2026-05-04

Abstract excerpt

<title>Abstract</title> <p> GLP-1 receptor agonists induce substantial weight loss, but the extent to which lean tissue and physical function are preserved in routine care remains poorly understood. Using an EHR-linked body-composition digital phenotyping pipeline with LLM-based extraction, we performed a large-scale longitudinal analysis of 670,422 first-episode GLP-1RA users, including 456,742 treated with sem...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
babb136c-ed73-56ae-bc81-942cc9930119
DOI
10.21203/rs.3.rs-9407186/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotypingDOI 10.21203/rs.3.rs-9407186/v1
Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotypingSemantic proximity
Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.Semantic proximity
Incident Frailty and Mortality Risk with Significant Tirzepatide-Associated Weight Loss in Medicare-Age PatientsSemantic proximity
Endogenous Incretin Secretagogue Compositions as a Mechanistic Class Versus Pharmacological Incretin Receptor Agonists for Weight Reduction in Overweight Adults: A Real-World Observational Cohort Analysis of a Nutraceutical Composition (Trimsulin) and Comparison with Published Outcomes for Semaglutide and TirzepatideSemantic proximity
Legacy neuropsychiatric benefit after semaglutide is linked to maximum achieved dose and independent of the maximum weight lostSemantic proximity
Current status of anti-obesity medications and performance, an EHR based surveySemantic proximity
Review of the Use of Digital Therapeutics for Obesity Treatment: Toward a Psychological Phenotyping.Semantic proximity
Influence of BMI-associated genetic variants and metabolic risk factors on weight loss with semaglutide: a longitudinal clinico-genomic cohort studySemantic proximity
Real-World Weight Loss and Telehealth Platform Utilization Patterns of Long-Term GLP-1 Receptor Agonist Treatment of self pay patients : A Retrospective AnalysisSemantic proximity
Integrating Precision Medicine and Digital Health in Personalized Weight Management: The Central Role of NutritionSemantic proximity
Neurosensory Risk After Semaglutide or Tirzepatide Is Lower Than Matched Antidiabetic and Bariatric Surgery Cohorts and Tracks Glycemic BurdenSemantic proximity
Oral Wegovy Broadens Care Continuum Across First-Time GLP-Starters, High Cardiometabolic Burden GLP-Switchers, and Medicare-Age PatientsSemantic proximity
Select a neighboring publication to make it the new centre.